Faculty of Medicine, The Hebrew University of Jerusalem, Department of Ophthalmology, Kaplan Medical Center, Israel; Ophthalmology Research Laboratory, Kaplan Medical Center, Rehovot, Israel.
Ophthalmology Research Laboratory, Kaplan Medical Center, Rehovot, Israel.
Exp Eye Res. 2021 Mar;204:108431. doi: 10.1016/j.exer.2020.108431. Epub 2021 Jan 3.
Uveal melanoma (UM) and conjunctival melanoma (CM) are ocular malignancies that give rise to life-threatening metastases. Although local disease can often be treated successfully, it is often associated with significant vision impairment and treatments are often not effective against metastatic disease. Novel treatment modalities that preserve vision may enable elimination of small tumors and may prevent subsequent metastatic spread. Very few mouse models of metastatic CM and UM are available for research and for development of novel therapies. One of the challenges is to follow tumor growth in-vivo and to determine the right size for treatment, mainly of the posterior, choroidal melanoma. Hence, the purpose of this study was to establish a simple, noninvasive imaging tool that will simplify visualization and tumor follow-up in mouse models of CM and UM. Tumors were induced by inoculation of murine B16LS9 cells into the sub-conjunctival or the choroidal space of a C57BL/6 mouse eye under a surgical microscope. Five to ten days following injection, tumor size was assessed by Phoenix MicronIV™ image-guided Optical Coherence Tomography (OCT) imaging, which included a real-time camera view and OCT scan of the conjunctiva and the retina. In addition, tumor size was evaluated by ultrasound and histopathological examination of eye sections. Tumor growth was observed 5-9 days following sub-conjunctival or sub-retinal injection of seven-thousand or seventy-thousand cells, respectively. A clear tumor mass was detected at these regions using the MicronIV™ imaging system camera and OCT scans. Histology of eye sections confirmed the presence of tumor tissue. OCT allowed an accurate measurement of tumor size in the UM model and a qualitative assessment of tumor size in the CM model. Moreover, OCT enabled assessing the success rate of the choroidal tumor induction and importantly, predicted final tumor size already on the day of cell inoculation. In conclusion, by using a simple, non-invasive imaging tool, we were able to follow intraocular tumor growth of both CM and UM, and to define, already at the time of cell inoculation, a grading scale to evaluate tumor size. This tool may be utilized for evaluation of new mouse models for CM and UM, as well as for testing new therapies for these diseases.
葡萄膜黑色素瘤 (UM) 和结膜黑色素瘤 (CM) 是引起危及生命的转移的眼部恶性肿瘤。尽管局部疾病通常可以成功治疗,但它常伴有严重的视力损害,并且治疗通常对转移性疾病无效。保留视力的新型治疗方法可能能够消除小肿瘤并可能阻止随后的转移扩散。用于研究和开发新疗法的转移性 CM 和 UM 的小鼠模型非常少。其中一个挑战是在体内跟踪肿瘤生长并确定治疗的正确大小,主要是针对脉络膜黑色素瘤。因此,本研究的目的是建立一种简单、非侵入性的成像工具,以简化 CM 和 UM 小鼠模型中的可视化和肿瘤随访。在手术显微镜下,将小鼠 B16LS9 细胞接种到结膜下或脉络膜空间中,诱导肿瘤。注射后 5-10 天,通过 Phoenix MicronIV™ 图像引导光学相干断层扫描 (OCT) 成像评估肿瘤大小,该成像包括实时相机视图和结膜和视网膜的 OCT 扫描。此外,通过超声和眼部分切片的组织病理学检查评估肿瘤大小。在分别注射 7000 或 70000 个细胞后 5-9 天观察到肿瘤生长。使用 MicronIV™ 成像系统相机和 OCT 扫描在这些区域检测到清晰的肿瘤肿块。眼部分切片的组织学证实了肿瘤组织的存在。OCT 允许在 UM 模型中准确测量肿瘤大小,并在 CM 模型中定性评估肿瘤大小。此外,OCT 能够评估脉络膜肿瘤诱导的成功率,并且重要的是,在细胞接种当天即可预测最终肿瘤大小。总之,通过使用简单、非侵入性的成像工具,我们能够跟踪 CM 和 UM 的眼内肿瘤生长,并在细胞接种时定义评估肿瘤大小的分级量表。该工具可用于评估 CM 和 UM 的新型小鼠模型,以及测试这些疾病的新疗法。